logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Axicabtagene ciloleucel for relapsed/refractory indolent non-Hodgkin lymphoma

< Back

Axicabtagene ciloleucel for relapsed/refractory indolent non-Hodgkin lymphoma

Drugs

Cancer and Palliative Care

August 2019


Axicabtagene ciloleucel is in clinical development as treatment for adult patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL). In NHL, the affected lymphocytes start to multiply in an abnormal way and begin to collect in certain parts of the body, such as the lymph nodes. Indolent, or low grade NHL tends to grow very slowly. Types of low-grade NHL include follicular and marginal zone lymphoma. Relapse means that the lymphoma has come back after going into complete remission. Lymphoma that does not go into remission with treatment is known as refractory lymphoma. Treatment options for relapsed/refractory indolent NHL after two priori treatments are limited.
Axicabtagene ciloleucel is an advanced therapy that contains the patient’s own white blood cell (T-cells) that have been modified genetically in the laboratory so that they make a protein called chimeric antigen receptor (CAR). The CAR T-cells attach to another protein on the surface of cancer cells and causing the cells to die. If licensed, axicabtagene ciloleucel will offer an additional treatment for patients with relapsed/refractory indolent NHL including follicular and marginal zone lymphoma.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts